Dare? Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Stock Information for Dare Bioscience Inc.
Loading
Please wait while we load your information from QuoteMedia.